Sign In
Buy AZN
$183.02
+2.00 (+1.10%)
At Close: Jun 24, 2026
AstraZeneca PLC (AZN) Q3 2024 Earnings Call Transcript
03:10pm, Tuesday, 12'th Nov 2024
AstraZeneca PLC (NASDAQ:AZN ) Q3 2024 Earnings Conference Call November 12, 2024 9:00 AM ET Company Participants Andy Barnett - Head, Investor Relations Pascal Soriot - Executive Director and CEO Arad
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC - AZN
02:30pm, Tuesday, 12'th Nov 2024
NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NASDAQ:AZN). Such investors are advise
AstraZeneca Lifts Outlook, Plans $3.5B US Investment
01:10pm, Tuesday, 12'th Nov 2024
British drugmaker AstraZeneca (AZN) increased its full-year sales outlook on booming demand for its cancer and rare-disease drugs, and said it plans to invest $3.5 billion in its U.S. business by the
Here's What Key Metrics Tell Us About Astrazeneca (AZN) Q3 Earnings
10:31am, Tuesday, 12'th Nov 2024
Although the revenue and EPS for Astrazeneca (AZN) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall
AstraZeneca Lifts 2024 Forecast On Better Than Expected Q3 Performance, Says It Takes China Investigations 'Very Seriously'
10:20am, Tuesday, 12'th Nov 2024
AstraZeneca Plc AZN reported third-quarter sales of $13.57 billion, up 18% year over year (+21% at constant currency), beating the consensus of $13.09 billion.
AstraZeneca: 450 million pound investment in UK under review amid talks with govt
09:32am, Tuesday, 12'th Nov 2024
London-listed drugmaker AstraZeneca said its plan to invest 450 million pounds ($576.7 million) in Britain for vaccine research and development, announced in March, is under review while talks with th
AstraZeneca boss says China arrests taken ‘very seriously'
09:27am, Tuesday, 12'th Nov 2024
AstraZeneca PLC (LSE:AZN) chief executive Pascal Soriot has signalled the company is taking a criminal probe into its Chinese business “very seriously”. Soriot on Tuesday said AstraZeneca would �
AstraZeneca Lifts Outlook, Plans $3.5B US Investment
09:11am, Tuesday, 12'th Nov 2024
British drugmaker AstraZeneca (AZN) increased its full-year sales outlook on booming demand for its cancer and rare-disease drugs, and said it plans to invest $3.5 billion in its U.S. business by the
Shareholder Rights Advocates at Levi & Korsinsky Investigate AstraZeneca PLC (AZN) Regarding Possible Securities Fraud Violations
07:25am, Tuesday, 12'th Nov 2024
NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of AstraZeneca PLC ("AstraZeneca PLC") (NASDAQ:AZN) concerning possible viola
AstraZeneca upgrades outlook for the second time on four months
03:28am, Tuesday, 12'th Nov 2024
AstraZeneca PLC (LSE:AZN) raised its 2024 sales and profit outlook for the second time in under four months, following stronger-than-expected third-quarter results. The Anglo-Swedish drugs giant now
AstraZeneca plans quick-fire $3.5bn US investment
03:14am, Tuesday, 12'th Nov 2024
AstraZeneca PLC (LSE:AZN) has announced a $3.5 billion investment to expand its research and manufacturing operations in the United States by 2026, with $2 billion allocated to creating more than 1,00
AstraZeneca lifts 2024 revenue and profit forecast after Q3 beat
02:06am, Tuesday, 12'th Nov 2024
Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time in less than four months on Tuesday, helped by resilient demand for its cancer and rare diseases medicines, after
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have submitted a new Biologics License Application (BLA) for accelerated approval in the
Will These 5 Biotech Stocks Surpass Q3 Earnings Forecasts?
11:50am, Monday, 11'th Nov 2024
Let's look at five biotech and drug companies, AZN, NVAX, AXSM, TBPH and PRTA, slated to release their third-quarter 2024 results this week.
AstraZeneca, Vodafone, Shell court ruling set the stage for busy Tuesday
10:58am, Monday, 11'th Nov 2024
A busy Tuesday will see AstraZeneca, Vodafone and Flutter all report, while UK unemployment figures and Shell's court ruling in the Netherlands will also be in focus.
